1. Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials

3. Overview

4. Case Study

5. Acute Intervention

6. Current Medications

7. Physical Exam/Lab Findings

8. Subjective

9. Red Flags for Risk of Nonadherence?

10. Helpful Tips

11. Ubiquity of the Nonadherence Problem

12. Addressing Barriers With the Patient as Partner

13. DAPT Trial: Stent Thrombosis and MACCE

14. PEGASUS: HRs and Rates of the Primary Endpoint

15. Relative Risks for All-Cause Mortality in Good vs Poor Adherence to Major CV Medications

16. The Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART)

17. Major Efficacy and Safety Endpoints in PLATO and SWEDEHEART

18. Case Study: 12-Month Visit

19. Factors Favoring Longer DAPT

20. Calculation of a DAPT Score

21. Multivariable Prediction Model and Derivation of the Score

22. Effect of Long (12- to 24-Month) vs Short (3- to 6-month) DAPT (ACS Subgroup)

23. New Paradigms

24. Clinical Decision Making Vision for the Future

25. Patient Engagement

26. Future of Medication Adherence

27. Concluding Remarks

28. Abbreviations

29. Abbreviations (cont)